Sarepta initiated with a Buy at Jefferies

Jefferies initiated coverage of Sarepta (SRPT) with a Buy rating and $165 price target Following Elevidys’ recent label expansion in Duchenne muscular dystrophy neuromuscular disease, doctor checks suggest the gene therapy can exceed consensus estimates of $2.1B in 2025 and produce “robust” cash flows through 2029, the analyst tells investors in a research note. After speaking to a few doctors about Elevidys’ uptake, the firm is confident the drug can generate over $2.2B in 2025 sales.